A348150 Stock Overview
Provides microbiome therapeutics for metabolic, immune, and neurological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
KoBioLabs, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,790.00 |
| 52 Week High | ₩14,150.00 |
| 52 Week Low | ₩5,970.00 |
| Beta | 0.69 |
| 11 Month Change | 18.03% |
| 3 Month Change | 1.30% |
| 1 Year Change | 7.01% |
| 33 Year Change | -70.71% |
| 5 Year Change | n/a |
| Change since IPO | -75.11% |
Recent News & Updates
Does KoBioLabs (KOSDAQ:348150) Have A Healthy Balance Sheet?
Sep 06
Cautious Investors Not Rewarding KoBioLabs, Inc's (KOSDAQ:348150) Performance Completely
Jul 12Recent updates
Does KoBioLabs (KOSDAQ:348150) Have A Healthy Balance Sheet?
Sep 06Cautious Investors Not Rewarding KoBioLabs, Inc's (KOSDAQ:348150) Performance Completely
Jul 12We're Not Worried About KoBioLabsInc's (KOSDAQ:348150) Cash Burn
Apr 15What Type Of Shareholders Own The Most Number of KoBioLabs,Inc (KOSDAQ:348150) Shares?
Feb 18Shareholder Returns
| A348150 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 25.2% | -0.5% | -0.5% |
| 1Y | 7.0% | 58.1% | 7.3% |
Return vs Industry: A348150 underperformed the KR Biotechs industry which returned 58.1% over the past year.
Return vs Market: A348150 matched the KR Market which returned 7.3% over the past year.
Price Volatility
| A348150 volatility | |
|---|---|
| A348150 Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in KR Market | 12.2% |
| 10% least volatile stocks in KR Market | 3.6% |
Stable Share Price: A348150's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A348150's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 50 | GwangPyo Ko | kobiolabs.com |
KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and neurological diseases. The company is based in Seongnam-si, South Korea.
KoBioLabs, Inc Fundamentals Summary
| A348150 fundamental statistics | |
|---|---|
| Market cap | ₩150.92b |
| Earnings (TTM) | -₩11.10b |
| Revenue (TTM) | ₩52.08b |
2.9x
P/S Ratio-13.6x
P/E RatioIs A348150 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A348150 income statement (TTM) | |
|---|---|
| Revenue | ₩52.08b |
| Cost of Revenue | ₩17.78b |
| Gross Profit | ₩34.30b |
| Other Expenses | ₩45.39b |
| Earnings | -₩11.10b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -572.71 |
| Gross Margin | 65.86% |
| Net Profit Margin | -21.30% |
| Debt/Equity Ratio | 27.4% |
How did A348150 perform over the long term?
See historical performance and comparison